TP53 and thymus lymphoma: We further analyzed a more sizable population of Ripk3+/+p53−/‐ (N = 42) and Ripk3−/−p53−/− DKO (N = 158) mice and found that over a period of 150 days, Ripk3−/−p53−/− DKO mice showed a decreased survival rate compared to Ripk3+/+p53−/‐ mice and a higher tumor incidence rate of thymic lymphoma (Figure 4B,C).